Homocysteine, B vitamins, and the risk of cardiovascular disease

Clinical Chemistry

Volumn 57, Issue 8, 2011, Pages 1201-1202

  Clarke, Robert ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; METHIONINE; PLACEBO; VITAMIN B GROUP;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG SAFETY; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; NEURAL TUBE DEFECT; NOTE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; PERIPHERAL VASCULAR DISEASES; RISK; VITAMIN B COMPLEX;

EID: 79961084060     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.164855     Document Type: Note

References (4)

1. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
2. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-12.
3. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010;303:2486-94.
4. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010;170:1622-31.